Trending News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #Research

This week in drug discovery (9-13 August)

News round-up by DDW’s Megan Thomas for 9-13 August This week, DDW’s Megan Thomas has rounded up five stories which report positive data and findings from around the globe in the drug discovery sector. Preclinical data on oral polymer-based duodenal exclusion therapy Glyscend has presented data during the American… Read More

#News #Trending News

#Cancer research #Technology #Therapeutics #Tumour biology

First patient dosed in AVA6000 pro-Doxorubicin Phase I clinical trial

Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. The pre|CISION platform incorporates a substrate that is specifically cleaved by the protease fibroblast activation protein alpha (FAPa), which is… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Assays #Covid-19 #Drug development

Human studies begin on AI Covid-19 treatment with up to 97% effectiveness

Skymount Medical and Louisiana State University (LSU) have commenced human studies on a unique combination of therapies for Covid-19 patients, known as SM-19. In vitro and in vivo assays conducted by the IIT Research Institute (IITRI) in Chicago showed significant efficacy in reducing viral load of the SARS-Cov-2 virus. The… Read More

#News #Trending News

#Biotechnology #Drug discovery #Exscientia #Technology

Exscientia builds automated laboratories to expand pipeline

Exscientia has announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, UK, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology. In parallel, Exscientia is building a new 26,000 square… Read More

#News #Trending News

#Clinical trials #Drug development #Lipidomics

Phase II clinical trial of ASC40 approved for acne treatment

Ascletis Pharma has announced that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne. The Phase II trial is a randomised, double-blind, placebo-controlled, multicentre clinical trial to be conducted in China to evaluate… Read More

#News #Trending News

#Biotherapeutics #Clinical trial #mRNA #Therapeutics

Positive interim results from Phase I study for sickle cell disease treatment

Massachusetts-headquartered Fulcrum Therapeutics has announced positive interim results from the ongoing single and multiple-ascending dose (SAD and MAD) Phase I trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent and selective small molecule inhibitor of EED designed to increase the expression of fetal hemoglobin (HbF) with the… Read More

#News #Trending News

Human liver
#Drug delivery #Drug discovery #Liver disease

FDA Fast Track designation for liver disease treatment

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US… Read More

#News #Trending News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Bioinformatics #Biomedical research #Neurodegenerative disorders #Neuroscience #Research

Novel research identifies gene targets of stress hormones in the brain

New research has moved a step forward in understanding how glucocorticoid hormones (‘stress hormones’) act upon the brain and what their function is. The findings could lead to more effective strategies in the prevention and treatment of mental health disorders. The study, led by academics at the University of Bristol… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

EC to purchase 200 million doses of Novavax NVX-CoV2373

Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for… Read More

#News #Trending News

#Biomedicine #Biotechnology #Events #Lab automation #Screening #SLAS #SLAS 2021

SLAS partners with AseBio and sponsors BioSpain 2021

The Society for Laboratory Automation and Screening (SLAS) has partnered with Spanish Bioindustry Association (AseBio) to support the intersection of economic, technological and business areas of biotechnology and biomedicine. As part of this partnership, SLAS will support BioSpain 2021 as a sponsor between September 27 and October 1, 2021 in… Read More

#News #Trending News

#Drug development #Immunology / Virology & Vaccines #mRNA #Therapeutics

Sanofi to acquire Translate Bio

Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More

#News #Trending News

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News

#Drug development #Drug discovery #Immuno-oncology #Infectious diseases #Neurodegenerative disorders

This week in drug discovery (26-29 July)

News round-up by DDW’s Megan Thomas for 26-19 July DDW’s Megan Thomas rounds up her top five stories this week which show how innovation in drug discovery is enhanced by collaboration, be it financial backing or through the combining of differing expertise to achieve a common goal. SARS-CoV-2 spike… Read More

#News #Trending News